MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

MAIA Biotechnology, Inc.AMEX: MAIA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $6.37M (cash outflow) rose 41.0% year over year, ahead of the +23.1% change in trailing-twelve-month net income. Sequentially, it rose 75.5% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$16.7M (-25.4%) for the fiscal year ending Dec 2026, a slowdown from the -3.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.37M+75.5% QoQ
Last fiscal yearDec 2025
-$22.4M-3.7% YoY
LTMMar 2026
-$24.25M+23.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.0%-33.9%-74.9 pp
1 year-3.7%-25.4%-21.7 pp
3-year CAGR+12.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(22.4M) USD
Year-over-year change
+3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 net income of $24.25M is the 4th largest of the 7 companies compared; the peer median is $25.04M.
  • Its year-over-year change of +23.1% is the 3rd highest of 6, against a peer median of +20.8%.
  • Over three fiscal years its annual growth of +12.4% compares with a peer median of +4.1%.
MAIA Competitors Peer median
Net Income for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$91.72M +58.4%—345.4%
ANVSAnnovis Bio, Inc.LTM Mar 2026$40.92M +40.8%+944.4%—
PYPDPolyPid Ltd.LTM Dec 2025$34.17M —-4.8%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$24.25M +23.1%+12.4%—
LTRNLantern Pharma Inc.LTM Mar 2026$15.91M -19.9%+6.3%—
VERUVeru Inc.LTM Mar 2026$14.3M -60.6%-35.3%—
RNXTRenovoRx, Inc.LTM Mar 2026$12.27M +20.8%+4.1%824.0%
Peer median (excluding MAIA) $25.04M+20.8%+4.1%584.7%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation2.72M2.32M3.09M1.91M2.63M
Change in Working Capital1.13M352.78K3.09M(1.24M)1.5M
Accounts Receivables0(269.4K)158.41K56.81K80.41K
Inventory00000
Accounts Payables805.52K211.35K471.9K(118.83K)519.72K
Other Working Capital320.23K410.83K2.46M(1.18M)899.19K
Other Non-Cash Items4.61M1M526.53K6.88M(579.4K)
Operating Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment7.43M0000
Common Stock Issued5.74M13.97M11.42M18.75M18.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities860.43K(1.5M)(2.15M)(578.1K)(617.13K)
Financing Cash Flow14.03M12.48M9.27M18.18M17.91M
Effect of Forex Changes0(4.43K)(117)(21.55K)(5.22K)
Net Change in Cash9.91M376.64K(3.8M)2.45M(943.27K)
Free Cash Flow(4.12M)(12.1M)(13.07M)(15.7M)(18.84M)

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.